Intech Investment Management LLC Decreases Stock Holdings in Vericel Corporation $VCEL

Intech Investment Management LLC decreased its stake in shares of Vericel Corporation (NASDAQ:VCEL) by 42.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,887 shares of the biotechnology company’s stock after selling 23,142 shares during the period. Intech Investment Management LLC owned about 0.06% of Vericel worth $972,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in VCEL. Abich Financial Wealth Management LLC bought a new stake in Vericel in the 3rd quarter worth approximately $31,000. Osaic Holdings Inc. boosted its stake in shares of Vericel by 13.7% in the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after buying an additional 353 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Vericel by 178.4% in the 2nd quarter. Smartleaf Asset Management LLC now owns 3,241 shares of the biotechnology company’s stock worth $135,000 after buying an additional 2,077 shares during the last quarter. AlphaQuest LLC grew its holdings in shares of Vericel by 135.6% in the third quarter. AlphaQuest LLC now owns 3,332 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 1,918 shares during the period. Finally, Connecticut Wealth Management LLC bought a new stake in shares of Vericel in the second quarter worth $201,000.

Vericel Price Performance

Shares of NASDAQ VCEL opened at $33.71 on Monday. Vericel Corporation has a 1 year low of $29.24 and a 1 year high of $50.36. The firm has a 50-day simple moving average of $36.80 and a two-hundred day simple moving average of $36.07. The company has a market cap of $1.71 billion, a P/E ratio of 108.74 and a beta of 1.22.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, February 26th. The biotechnology company reported $0.45 EPS for the quarter, meeting analysts’ consensus estimates of $0.45. Vericel had a return on equity of 5.17% and a net margin of 5.98%.The firm had revenue of $92.92 million for the quarter, compared to analysts’ expectations of $92.66 million. During the same quarter in the prior year, the firm posted $0.38 earnings per share. The company’s quarterly revenue was up 23.3% on a year-over-year basis. As a group, equities research analysts expect that Vericel Corporation will post 0.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Vericel in a report on Monday, December 29th. Zacks Research downgraded Vericel from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. Wall Street Zen lowered shares of Vericel from a “buy” rating to a “hold” rating in a research report on Saturday. Truist Financial lowered their price objective on shares of Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Finally, HC Wainwright raised their price objective on shares of Vericel from $60.00 to $64.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $58.50.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.